Testing JAK-3 Kinase inhibitor in cerebral Malaria animal model

Status
Completed
Start date
End date
Start stage
Screening
End stage
Hit ID
Disease
Malaria
Research areas
Drug

Dr. Gros studied cerebral malaria (CM). CM is the most severe neurological complication of a Plasmodium falciparum infection, resulting in seizures, coma, and death. CM is characterized by severe inflammation in the brain, and it is this inflammation that makes the disease invariably lethal. Anti-inflammatory compounds may help to prevent this inflammation-associated brain damage. Janus kinase 3 (JAK-3) is a key enzyme in an important inflammation-signaling pathway, and thus inhibiting JAK-3 could inhibit cerebral inflammation. BVGH connected Dr. Gros with Pfizer, which shared a JAK-3 inhibitor with suitable characteristics for testing in Dr. Gros’ CM animal model.